''' I almost became a statistic.
Another founder with a failed AI startup. We had the brilliant tech, the PhDs from Stanford, and a model that was, on paper, revolutionary. We were burning through our seed round at an alarming rate, and for all our technical brilliance, we were getting precisely zero traction. The metrics were flat. The customers weren’t buying. The team was getting demoralized. I could feel the walls closing in.
Most founders think building a great AI model is enough. They're wrong. Here's the uncomfortable truth about what it really takes to succeed in the brutal, regulated world of healthcare AI.
The Seductive Lie of the Perfect Algorithm
Our first idea was ambitious, I’ll give it that. We were going to revolutionize radiology. Our model could detect certain anomalies in medical images with 98.7% accuracy in our lab environment. We thought we had it made. We’d sell it to every hospital system in the country, and the money would pour in. We spent a year and a half and $2 million perfecting the algorithm.
We were so focused on the tech that we missed the most important part: the workflow. We walked into sales meetings with hospital administrators and heads of radiology, and their eyes would glaze over. They didn’t care about our model’s F1 score. They cared about reimbursement codes, integration with their 20-year-old electronic health record (EHR) system, and how this would slow down their already overworked radiologists.
Our "revolutionary" tool was just another screen, another login, another step in a convoluted process. We weren’t solving a problem; we were creating a new one. We had a hammer, and we were desperately looking for a nail, instead of understanding what the carpenters actually needed.
The Confrontation
I remember the board meeting like it was yesterday. Our lead investor, a guy who’d seen it all, looked at our burn rate and our customer acquisition cost—which was basically infinite—and he laid it out. "You have six months of runway left," he said, not unkindly. "Either you find a real problem to solve, or you start winding this thing down."
That was a punch to the gut. All that work, all that belief, was about to evaporate. That night, I couldn’t sleep. I went back through every note from every sales call we’d ever had. I was looking for a pattern, a whisper of a real need. And then I found it.
In a call with a pharma executive, a casual comment he made stuck out. He was complaining about the sheer cost and time of preclinical drug trials. "We spend a billion dollars and a decade to get one drug to market," he’d said. "And most of that time is spent on compounds that fail. If we could just predict which ones would fail earlier, we’d save hundreds of millions."
That was it. That was the real, hair-on-fire problem.
The Pivot to a $10M Niche
We didn't need a new algorithm. We needed a new target. We took our core imaging AI and repurposed it. Instead of looking for anomalies in X-rays, we trained it to analyze cellular assays from early-stage drug candidates. Our new pitch wasn’t about a fancy AI; it was about money and time.
We could tell a pharma company, with a high degree of certainty, which of their thousand potential drug compounds were likely to show toxic effects before they spent millions on further testing. We weren’t a radiology tool anymore. We were a de-risking engine for drug discovery.
We built a simple dashboard. No complicated integration. The pharma companies would send us their assay data, and we’d send them back a report: these 50 compounds have a high probability of failure. Focus on the other 950.
The first contract we signed was for $500,000. It wasn’t a massive deal, but it was more revenue than we had made in the previous two years combined. It was validation. Within 18 months, we had signed contracts with three major pharmaceutical companies, totaling over $10 million in annual recurring revenue.
We didn’t just survive. We thrived.
Lessons for Founders in the Trenches
Looking back, the near-death experience was the best thing that could have happened to us. It forced us to confront some hard truths about building in the healthcare space.
Sell the Outcome, Not the Tech: Nobody cares about your AI. They care about what it can do for them. Does it save money? Does it save time? Does it improve patient outcomes in a way that can be measured and billed? Start with the business problem, the real-world pain, and work backward.
The Workflow is Everything: A brilliant AI that disrupts the existing workflow is useless. You have to fit into how doctors and researchers already work. Your solution needs to be as seamless as possible, requiring minimal change to their daily habits. The path of least resistance is the only path to adoption in a hospital or a lab.
Niches are Where the Money Is: We tried to boil the ocean with a general radiology tool. We found success when we focused on a very specific, very expensive problem for a very specific customer. Don’t be afraid to go narrow. Find a small group of people with a billion-dollar problem.
Regulation is Not a Moat, It’s the Playing Field: So many tech founders are scared of healthcare because of HIPAA and the FDA. That’s a huge mistake. The regulations are the rules of the game. Learn them, build for them, and use them to your advantage. If you can navigate the compliance, you create a barrier to entry that less-focused competitors can’t cross.
I’ve seen this pattern again and again in my own startups and in the 200+ companies I’ve invested in. The winners in AI healthcare aren’t the ones with the most complex models. They are the ones who are most obsessed with solving a real, painful, and expensive problem for their customers.
So if you’re a founder in this space, I urge you to get out of the lab. Stop tweaking your model. Go talk to your customers. Find their pain. And then, and only then, build the solution. Your startup’s life depends on it. '''))]}>, "path": "/home/ubuntu/how-my-ai-startup-almost-died-before-we-5.md", "text": "I almost became a statistic.
Another founder with a failed AI startup. We had the brilliant tech, the PhDs from Stanford, and a model that was, on paper, revolutionary. We were burning through our seed round at an alarming rate, and for all our technical brilliance, we were getting precisely zero traction. The metrics were flat. The customers weren’t buying. The team was getting demoralized. I could feel the walls closing in.
Most founders think building a great AI model is enough. They're wrong. Here's the uncomfortable truth about what it really takes to succeed in the brutal, regulated world of healthcare AI.
The Seductive Lie of the Perfect Algorithm
Our first idea was ambitious, I’ll give it that. We were going to revolutionize radiology. Our model could detect certain anomalies in medical images with 98.7% accuracy in our lab environment. We thought we had it made. We’d sell it to every hospital system in the country, and the money would pour in. We spent a year and a half and $2 million perfecting the algorithm.
We were so focused on the tech that we missed the most important part: the workflow. We walked into sales meetings with hospital administrators and heads of radiology, and their eyes would glaze over. They didn’t care about our model’s F1 score. They cared about reimbursement codes, integration with their 20-year-old electronic health record (EHR) system, and how this would slow down their already overworked radiologists.
Our
Frequently Asked Questions
How can I apply this thinking to my own situation?
Start by identifying the core principle behind the opinion, not the specific example. Then ask yourself: does this principle apply to my context? If yes, test it in a small, low-risk way before going all in.
Do all experts agree with this view?
No, and that's fine. The best ideas in business are often contrarian. I share my perspective based on my experience and data, but I encourage you to seek out opposing viewpoints and form your own conclusions.
How has this view evolved over time?
My thinking on most topics has changed significantly over the years. Early in my career, I held many conventional views that experience proved wrong. I try to update my beliefs when the evidence changes.
What experience informs this perspective?
This perspective comes from over a decade of building companies in Silicon Valley, two successful exits (RemoteTeam to Gusto, MovieLaLa to Gfycat), and investing in 200+ startups including Anthropic, OpenAI, and Scale AI. I write about what I've lived.